Innovations in Biosimilars and Monoclonal Antibodies

Explore the newest adalumumab biosimilar, RYVK, advancements in lupus incidence rates, and the connection between tosyllismab use and infection risk. Discover FDA approvals of drugs targeting the neonatal fc receptor and exciting progress with nipple calamab in RA and other conditions.